Lipid Emulsion in Cardiac Valve Replacement Surgery

• Status: Not yet recruiting
• Trial end date: 2023-10-01
• Target enrollment: 0
• Participant gender: All

Summary

Myocardial protection has become an essential adjunctive measure in cardiac surgery to bail the myocardium out of ischemia/reperfusion-induced damage during the operation.

Experimental studies have shown that lipid emulsion infusion just before reperfusion (i.e., intralipid postconditioning (ILPC)) could reduce myocardial infarct sizes, improve cardiac function, and reduce myocardial I/R injuries, despite the interesting experimental findings, the potential clinical usage of lipid emulsion in preventing myocardial I/R injury needs to be further investigated.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Assiut University
• Treatments: SMOFlipid

Criteria

Inclusion Criteria:

• patients undergoing rheumatic valve replacement surgery

• elective surgery

• age between 18 and 80 years old

• left ventricular ejection fraction > 0.4

Exclusion Criteria:

• Emergency and Re do surgery,

• Positive base line CTnI or CK-MB,

• Preoperative treatment with intralipid in the last 1 month.

• History of allergy to (peanut, eggs, and soya bean)

• Implanted pacemaker,

• previous myocardial infarction,

• Diabetic or other metabolic disorders,

• Significant Renal impairment (Cr > 1.5) or on hemodialysis

• Significant hepatic dysfunction (INR>2)

• Drugs interfere as (cyclosporine)

• Infection (WBC >12)